9/16/2013 10:29:14 AM
JERUSALEM & LONDON--(BUSINESS WIRE)--Cancer Research Technology Ltd. (CRT), Cancer Research UK’s technology development arm, and Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) have signed a multi-project alliance agreement to research and develop first-in-class cancer drugs that modulate DNA damage and repair response (DDR) processes in cancer cells.
Help employers find you! Check out all the jobs and post your resume.
comments powered by